My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

428.38 -8.49 (-1.94%)

Streaming Delayed Price Updated: 1:26 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024 ↗

April 15, 2024

Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades.

Via InvestorPlace

2 Under-the-Radar Growth Stocks to Consider ↗

April 10, 2024

Don't ignore these innovative companies.

Via The Motley Fool

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics ↗

April 05, 2024

These businesses should see good times ahead.

Via The Motley Fool

1 No-Brainer Growth Stock to Buy Now ↗

April 03, 2024

This liver-disease specialist might be significantly undervalued.

Via The Motley Fool

The 3 Best Biotech Stocks to Buy in April 2024 ↗

April 01, 2024

Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April.

Via InvestorPlace

2 Top Biotech Buyout Candidates ↗

March 31, 2024

Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be...

Via Talk Markets

Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock ↗

March 26, 2024

This biotech just got clearance to dive into a deep ocean of a market.

Via The Motley Fool

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading

March 15, 2024

Via Investor Brand Network

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗

March 29, 2024

Both stocks are pretty risky, but one of them more so than the other.

Via The Motley Fool

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? ↗

March 29, 2024

Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?

Via The Motley Fool

7 Stocks That Will Drive the Weight Loss Drugs Market

March 28, 2024

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

Via MarketBeat

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? ↗

March 22, 2024

The mid-cap biotech has succeeded where many others failed.

Via The Motley Fool

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? ↗

March 19, 2024

Madrigal has one key advantage over its two huge potential future rivals.

Via The Motley Fool

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

March 18, 2024

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

March 18, 2024

Via Benzinga

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗

March 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Via The Motley Fool

FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring ↗

March 15, 2024

FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease....

Via Benzinga

Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 15, 2024

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.

Via Benzinga

Why Is Geron (GERN) Stock Up 94% Today? ↗

March 15, 2024

Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing.

Via InvestorPlace

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday ↗

March 15, 2024

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported...

Via Benzinga

Topics Stocks

MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today ↗

March 15, 2024

Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 15, 2024

Via Benzinga

Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗

March 15, 2024

Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 15, 2024

It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 14, 2024

Via Benzinga

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 14, 2024

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Via Benzinga

Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH ↗

March 14, 2024

The company hopes to be the first to the finish line with a treatment for MASH.

Via Investor's Business Daily

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗

March 09, 2024

Good news could be in store for all three of these drugmakers.

Via The Motley Fool

1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? ↗

March 05, 2024

This business could be on the cusp of making medical history.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.